In a world where healthcare is being redefined by innovation and resilience, we sat down with Astrid der Weduwe, Investor Relations at Kieger, to understand how to invest with purpose. From navigating geopolitical shifts to spotting real-world impact beyond the hype, Astrid shares how Kieger identifies the companies truly transforming healthcare. An insightful conversation on long-term value, responsible capital, and the future of health.
Global partnerships in healthcare are on the rise. How is this changing innovation, and what does it mean for your investments?
A: While global collaborations are reshaping healthcare innovation, recent geopolitical developments have underscored the importance of supply chain resilience. At Kieger, we focus on companies operating in developed markets with robust and transparent supply chains. We prioritize investments in businesses that contribute to healthcare resilience through innovation in diagnostics, therapeutics, and care delivery. This approach ensures alignment with our mandate and reduces exposure to geopolitical risks.
Healthcare systems are under pressure. What makes a company part of the solution—and a good investment?
A: The best companies help healthcare systems do more with less—whether through better diagnostics, lower-cost therapies, or smarter delivery of care. We invest in businesses that not only grow sustainably but also strengthen the system over time. That resilience is what gives them lasting value.
There’s a lot of talk about AI, real-world data, and genomics. How do you manage risk while still investing in these trends?
A: We’re excited about innovation—but we don’t chase hype. We invest in companies where these technologies are already improving outcomes or driving efficiencies. At the same time, we focus on fundamentals: strong management, clear business models, and evidence of clinical and commercial traction. That’s how we manage risk while staying exposed to upside potential.
Healthcare is evolving quickly. What skills do you need today to invest well in this sector?
A: Understanding financials is no longer enough. You need to grasp the science, the regulation, and how emerging technologies are changing the landscape. Our team combines medical and investment expertise so we can underwrite innovation with confidence—not just react to headlines.
How do you spot opportunity before the market does?
A: We monitor scientific progress, regulatory developments, and policy changes closely. Often, the real opportunity emerges before it’s visible in the numbers. That’s where our experience and network are key—identifying companies at a tipping point, whether it’s after a pivotal clinical trial or a new reimbursement decision.
Should investors in healthcare just provide capital, or do they need to be more involved?
A: In our view, investors have a role to play beyond capital. We actively engage with companies on strategy, governance, and sustainability. Strong partnerships between investors and companies lead to better long-term outcomes—for both patients and portfolios.